These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31569615)

  • 21. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications.
    Tsolaki V; Zarogiannis S; Zygoulis P; Kalomenidis I; Jagirdar R; Makris D; Daniil Z; Magkouta S; Triantafyllou I; Papanikolaou J; Gourgoulianis KI; Zakynthinos E
    Respirology; 2020 Oct; 25(10):1060-1065. PubMed ID: 32124515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
    Zhang W; Wu X; Wu L; Zhang W; Zhao X
    Ann Transl Med; 2015 Aug; 3(13):182. PubMed ID: 26366399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
    J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant pleural mesothelioma.
    Chen SE; Pace MB
    Am J Health Syst Pharm; 2012 Mar; 69(5):377-85. PubMed ID: 22345416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids.
    Gendre DAJ; Ameti E; Karenovics W; Perriraz-Mayer N; Triponez F; Serre-Beinier V
    Oncotarget; 2021 Nov; 12(24):2375-2387. PubMed ID: 34853659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma.
    Goudar RK
    Ther Clin Risk Manag; 2008 Feb; 4(1):205-11. PubMed ID: 18728709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standard therapy for the treatment of malignant pleural mesothelioma.
    Vogelzang NJ
    Lung Cancer; 2005 Oct; 50 Suppl 1():S23-4. PubMed ID: 16291429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
    Budde LS; Hanna NH
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forchlorfenuron and Novel Analogs Cause Cytotoxic Effects in Untreated and Cisplatin-Resistant Malignant Mesothelioma-Derived Cells.
    Henzi T; Diep KL; Oberson A; Salicio V; Bochet CG; Schwaller B
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells.
    Costa A; Forte IM; Pentimalli F; Iannuzzi CA; Alfano L; Capone F; Camerlingo R; Calabrese A; von Arx C; Benot Dominguez R; Quintiliani M; De Laurentiis M; Morrione A; Giordano A
    Front Oncol; 2024; 14():1418951. PubMed ID: 39011477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
    Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
    Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
    Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
    J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.
    Kanai O; Fujita K; Nakatani K; Mio T
    Respirol Case Rep; 2016 Mar; 4(1):28-31. PubMed ID: 26839699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
    Cinausero M; Rihawi K; Sperandi F; Melotti B; Ardizzoni A
    J Thorac Dis; 2018 Jan; 10(Suppl 2):S304-S310. PubMed ID: 29507800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
    J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
    Walter RFH; Sydow SR; Berg E; Kollmeier J; Christoph DC; Christoph S; Eberhardt WEE; Mairinger T; Wohlschlaeger J; Schmid KW; Mairinger FD
    Cancer Manag Res; 2019; 11():8711-8720. PubMed ID: 31576173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.